Autopsy report · NCT03803254

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“No participants enrolled”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Sun Yat-sen University
Sponsor type: University, hospital or other
Conditions: Hepatocellular Carcinoma
Interventions: Hepatic arterial infusion chemotherapy; Folfox Protocol; Lenvatinib; PD-1 antibody
Participants: 0
Sites: 3
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.